Engineered t cells target hidden leukemia cells in new trial

NCT ID NCT07645469

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a protein called WT1 found on leukemia cells, combined with the chemotherapy drug azacitidine. The goal is to find a safe dose and see if this approach can help the immune system clear the remaining cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FH-WT1-E50 TCR T cells and azacitidine
What this could lead to: If successful, this approach could offer a new way to eliminate remaining leukemia cells in patients with minimal residual disease, potentially preventing relapse.
What could go wrong: This is an early phase I trial with only 9 participants, so safety and dosing are still being established. The treatment may cause severe side effects or may not effectively control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.